Navigation Links
Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference

SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that Timothy I. Still, President and CEO of Accumetrics, and Gregory J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference being held in New York City on December 1-2, 2009 at The Palace Hotel.

This presentation comes on the heels of Accumetrics' VerifyNow P2Y12 Test being one of multiple methods recently evaluated during a Late Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2009.

Accumetrics' presentation will be on Tuesday, December 1, 2009 at 9:10 am eastern time. Management will also be available for one-on-one meetings with investors participating in Piper Jaffray's Health Care Conference. For those who would like to schedule an appointment with Accumetrics' management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at or contact your Piper Jaffray representative.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient(TM)) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly and Company.

Megan Rusnack
Lippert/Heilshorn & Associates

Timothy I. Still
President and CEO

SOURCE Accumetrics, Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accumetrics Announces $16.5M in New Capital Financing
2. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
3. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
4. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
5. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
6. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
7. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
8. Zimmer Holdings to Present at 21st Annual Piper Jaffray Health Care Conference
9. Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
10. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South ... 750,000. The digital component is distributed nationally, through a vast social media strategy ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... medical opinion process, participated in the 61st annual Employee Benefits Conference. The Employee ... took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was ...
Breaking Medicine News(10 mins):